RxDoctor Payments Data

Brian Mannion, MD

Hematology & Oncology · Cincinnati, OHNPI 1851387039

Payments from drug & device makers

$560in general payments, 2019–2025

Across 19 payments — averaging $29.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ASD Specialty Healthcare, LLC$71
  • Incyte Corporation$65
  • Blueprint Medicines Corporation$55
  • Exelixis Inc.$46
  • Regeneron Healthcare Solutions, Inc.$39
  • Novartis$39
  • plus $246 from 10 others

What the payments were for

  • Food & beverage$51892%
  • Education$428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$560 in reported general payments places this provider in the 20th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,961,369
Medicare patients
459
Services billed
75,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate20$519,529
PomalystPomalidomide22$513,760
Lenalidomide42$511,739
ErleadaApalutamide33$498,479
WeliregBelzutifan13$387,551
RevlimidLenalidomide19$347,073
XtandiEnzalutamide23$324,200
Abiraterone Acetate131$293,496
SprycelDasatinib13$242,676
IbrancePalbociclib14$221,650
JakafiRuxolitinib Phosphate11$193,141
LumakrasSotorasib11$185,767
ImbruvicaIbrutinib11$180,196
TasignaNilotinib Hcl12$118,178
EliquisApixaban66$53,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$17$756,43735 claims
Johnson & JohnsonErleada, Xarelto$25$533,19467 claims
Exelixis Inc.Cabometyx$46$519,52920 claims
MerckWelireg$26$387,55113 claims
Astellas Pharma US IncXtandi$21$324,20023 claims
Incyte CorporationJakafi$65$193,14111 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$25$180,19611 claims
NovartisTasigna$39$118,17812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →